Your browser doesn't support javascript.
loading
Association of Baseline and Pharmacodynamic Biomarkers With Outcomes in Patients Treated With the PD-1 Inhibitor Budigalimab.
Lambert, Stacie L; Zhang, Chun; Guo, Claire; Turan, Tolga; Masica, David L; Englert, Stefan; Fang, Yuni; Sheridan, James; McLaughlin, Robert Tyler; Tribouley, Catherine; Vosganian, Greg; Afar, Daniel.
Affiliation
  • Lambert SL; Oncology Early Development.
  • Zhang C; Discovery and Exploratory Statistics.
  • Guo C; Discovery and Exploratory Statistics.
  • Turan T; Genomics Research Center.
  • Masica DL; Genomics Research Center.
  • Englert S; Data and Statistical Sciences, AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
  • Fang Y; Drug Metabolism, Pharmacokinetics, AbbVie Inc, Redwood City, CA.
  • Sheridan J; Drug Metabolism, Pharmacokinetics, AbbVie Inc, Redwood City, CA.
  • McLaughlin RT; Genomics Research Center.
  • Tribouley C; Oncology Early Development.
  • Vosganian G; Oncology Early Development.
  • Afar D; Oncology Early Development.
J Immunother ; 45(3): 167-179, 2022 04 01.
Article in En | MEDLINE | ID: mdl-35034046
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Head and Neck Neoplasms / Lung Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2022 Type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Non-Small-Cell Lung / Head and Neck Neoplasms / Lung Neoplasms / Antineoplastic Agents Type of study: Prognostic_studies / Risk_factors_studies Limits: Humans Language: En Journal: J Immunother Journal subject: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Year: 2022 Type: Article